Ursula Dietrich

Dr. Ursula Dietrich

Georg-Speyer-Haus
orcid

Research Focus & Metrics

Academic Career Length

47Years (1980-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1983 in Wilhelm Roux' Archiv für Entwicklungsmechanik der Organismen
Verified
Journal Article
Closed access
PDF file
RLRuth Lehmann
Ruth Lehmann
UDUrsula Dietrich
Ursula Dietrich
FJFernando Jiménez
Fernando Jiménez
JCJosé A. Campos-Ortega
José A. Campos-Ortega

24 July 2005 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
JSJana Sticht
Jana Sticht
MHMichael Humbert
Michael Humbert
SFStuart Findlow
Stuart Findlow
JBJochen Bodem
Jochen Bodem
BMBarbara Mueller
Barbara Mueller
HKHans-Georg Kräusslich
Hans-Georg Kräusslich

30 June 2014 in Cancer Research
Verified
Journal Article
Open access
PDF file
AMAlexander Muik
Alexander Muik
LSLawton J. Stubbert
Lawton J. Stubbert
RJRoza Z. Jahedi
Roza Z. Jahedi
YGYvonne Geiβ
Yvonne Geiβ
JKJanine Kimpel
Janine Kimpel
Dorothee Von LaerDorothee Von Laer
Dorothee Von Laer
As cancer treatment tools, oncolytic viruses (OV) have yet to realize what some see as their ultimate clinical potential. In this study, we have engineered a chimeric vesicular stomatitis virus (VSV) that is devoid of its natural neurotoxicity while retaining potent oncolytic activity. The envelope glycoprotein (G) of VSV was replaced with a variant glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GP), creating a replicating therapeutic, rVSV(GP), that is benign in normal brain but can effectively eliminate brain cancer in multiple preclinical tumor models in vivo. Furthermore, it can be safely administered systemically to mice and displays greater potency against a spectrum of human cancer cell lines than current OV candidates. Remarkably, rVSV(GP) escapes humoral immunity, thus, for the first time, allowing repeated systemic OV application without loss of therapeutic efficacy. Taken together, rVSV(GP) offers a considerably improved OV platform that lacks several of the major drawbacks that have limited the clinical potential of this technology to date. Cancer Res; 74(13); 3567–78. ©2014 AACR.

1 January 1984 in Journal of Neurogenetics
Verified
Journal Article
Closed access
PDF file
UDUrsula Dietrich
Ursula Dietrich
JCJose A. Campos-Ortega
Jose A. Campos-Ortega
Six zygotically expressed genomic loci of Drosophila melanogaster, N, bib, mam, neu, Dl and E (spl), have previously been found to be involved in the commitment of ectodermal cells as neuroblasts. We have studied phenotypes induced by various mutant alleles at these 6 loci in imaginal epidermal cells, in order to assess possible implications of the genes in functions other than early neurogenesis. When homozygous, any of these mutations except bib affected the development of bristles and compound eye in various ways. These range from cell death to the production of additional bristles and several defects in ommatidial patterning, depending on the allele used. In contrast clones of bib homozygous cells exhibited wild-type phenotypes. The differences found in the expression of the neurogenic genes are discussed with respect to a hypothesis on the genetic control of neurogenesis.

1 July 1981 in Wilhelm Roux' Archiv für Entwicklungsmechanik der Organismen
Verified
Journal Article
Closed access
PDF file
RLRuth Lehmann
Ruth Lehmann
UDUrsula Dietrich
Ursula Dietrich
FJF. Jiménez
F. Jiménez
JCJ. A. Campos-Ortega
J. A. Campos-Ortega

1 June 2011 in Journal of Virology
Verified
Journal Article
Open access
AMAlexander Muik
Alexander Muik
IKInna Kneiske
Inna Kneiske
MWMarina Werbizki
Marina Werbizki
Doris WilflingsederDoris Wilflingseder
Doris Wilflingseder
TGTsanan Giroglou
Tsanan Giroglou
Dorothee Von LaerDorothee Von Laer
Dorothee Von Laer
Vesicular stomatitis virus (VSV)-based oncolytic virotherapy has the potential to significantly improve the prognosis of aggressive malignancies such as brain cancer. However, VSV's inherent neurotoxicity has hindered clinical development so far. Given that this neurotropism is attributed to the glycoprotein VSV-G, VSV was pseudotyped with the nonneurotropic envelope glycoprotein of the lymphocytic choriomeningitis virus (LCMV-GP→VSV-GP). Compared to VSV, VSV-GP showed enhanced infectivity for brain cancer cells in vitro while sparing primary human and rat neurons in vitro and in vivo , respectively. In conclusion, VSV-GP has a much wider therapeutic window than VSV and is thus more suitable for clinical applications, especially in the brain.